Evidence map›Paper›PMID 22954700›Full record

ArticleCancer biology & therapy2012

Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo.

Benedikt Feuerecker, Sabine Pirsig, Christof Seidl, Michaela Aichler, Annette Feuchtinger, Gernot Bruchelt, Reingard Senekowitsch-Schmidtke

Open access · bronzeAbstract read
In one paragraph

Article in Cancer biology & therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Alpha-Lipoic Acid: Biological Mechanisms and Health Benefits.Antioxidants (Basel, Switzerland) · 2024
    Review
  11. Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  12. Review
  13. Article
  14. Article
  15. Molecular and Therapeutic Insights of Alpha-Lipoic Acid as a Potential Molecule for Disease Prevention.Revista brasileira de farmacognosia : orgao oficial da Sociedade Brasileira de Farmacognosia · 2023
    Review
  16. Article
  17. Article
  18. Review
  19. Metabolic Strategies for Inhibiting Cancer Development.Advances in nutrition (Bethesda, Md.) · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Benedikt FeuereckerDepartment of Nuclear Medicine, Technische Universitaet Muenchen, Munich, Germany.
Sabine Pirsig
Christof Seidl
Michaela Aichler
Annette Feuchtinger
Gernot Bruchelt
Reingard Senekowitsch-Schmidtke
Munich University of Applied Sciences · DEHelmholtz Zentrum München · DETaipei Institute of Pathology · TWUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer cells convert glucose preferentially to lactate even in the presence of oxygen (aerobic glycolysis-Warburg effect). New concepts in cancer treatment aim at inhibition of aerobic glycolysis. Pyruvate dehydrogenase converts pyruvate to acetylCoA thus preventing lactate formation. Therefore, the aim of this study was to evaluate compounds that could activate pyruvate dehydrogenase in cancer cells. We investigated the effects of (R)-(+)-α-lipoic acid (LPA) and dichloroacetate (DCA), possible activators of pyruvate dehydrogenase, on suppression of aerobic glycolysis and induction of cell death. The neuroblastoma cell lines Kelly, SK-N-SH, Neuro-2a and the breast cancer cell line SkBr3 were incubated with different concentrations (0.1-30 mM) of LPA and DCA. The effects of both compounds on cell viability/proliferation (WST-1 assay), [18F]-FDG uptake, lactate production and induction of apoptosis (flow cytometric detection of caspase-3) were evaluated. Furthermore, NMRI nu/nu mice that had been inoculated s.c. with SkBr3 cells were treated daily for four weeks with LPA (i.p, 18.5 mg/kg) starting at day 7 p.i.. Tumor development was measured with a sliding caliper and monitored via [18F]-FDG-PET. Residual tumors after therapy were examined histopathologically. These data suggests that LPA can reduce (1) cell viability/proliferation, (2) uptake of [18F]-FDG and (3) lactate production and increase apoptosis in all investigated cell lines. In contrast, DCA was almost ineffective. In the mouse xenograft model with s.c. SkBr3 cells, daily treatment with LPA retarded tumor progression. Therefore, LPA seems to be a promising compound for cancer treatment.

Indexed as

AnimalsApoptosisCaspase 3Cell Line, TumorCell ProliferationCell SurvivalDichloroacetic AcidFemaleGlucoseGlycolysisKetone OxidoreductasesMammary Neoplasms, AnimalMiceMice, NudeNeoplasm TransplantationNeuroblastomaCaspase 3Dichloroacetic AcidGlucoseKetone Oxidoreductasespyruvate dehydrogenase (NADP+)Thioctic Acid

Identifiers

PMID22954700
PMCPMC3542233
OpenAlexW2055782963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.